Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial.
Koch R, Haveman L, Ladenstein R, Brichard B, Jürgens H, Cyprova S, van den Berg H, Hassenpflug W, Raciborska A, Ek T, Baumhoer D, Egerer G, Kager L, Renard M, Hauser P, Burdach S, Bovee JVMG, Hong AM, Reichardt P, Kruseova J, Streitbürger A, Kühne T, Kessler T, Bernkopf M, Butterfaß-Bahloul T, Dhooge C, Bauer S, Kiss J, Paulussen M, Bonar F, Ranft A, Timmermann B, Rascon J, Vieth V, Kanerva J, Faldum A, Hartmann W, Hjorth L, Bhadri VA, Metzler M, Gelderblom H, Dirksen U. Koch R, et al. Among authors: hong am. Clin Cancer Res. 2023 Dec 15;29(24):5057-5068. doi: 10.1158/1078-0432.CCR-23-1966. Clin Cancer Res. 2023. PMID: 37843857 Clinical Trial.
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, van den Berg H, Hassenpflug W, Raciborska A, Ek T, Baumhoer D, Egerer G, Eich HT, Renard M, Hauser P, Burdach S, Bovee J, Bonar F, Reichardt P, Kruseova J, Hardes J, Kühne T, Kessler T, Collaud S, Bernkopf M, Butterfaß-Bahloul T, Dhooge C, Bauer S, Kiss J, Paulussen M, Hong A, Ranft A, Timmermann B, Rascon J, Vieth V, Kanerva J, Faldum A, Metzler M, Hartmann W, Hjorth L, Bhadri V, Dirksen U. Koch R, et al. J Clin Oncol. 2022 Jul 20;40(21):2307-2320. doi: 10.1200/JCO.21.01942. Epub 2022 Apr 15. J Clin Oncol. 2022. PMID: 35427190 Clinical Trial.
Mesenchymal chondrosarcoma: An Australian multi-centre cohort study.
Strach MC, Grimison PS, Hong A, Boyle R, Stalley P, Karim R, Connolly EA, Bae S, Desai J, Crowe P, Singhal N, Bhadri VA. Strach MC, et al. Cancer Med. 2023 Jan;12(1):368-378. doi: 10.1002/cam4.4849. Epub 2022 May 23. Cancer Med. 2023. PMID: 35603739 Free PMC article.
Presumed choroidal metastasis from soft tissue myoepithelial carcinoma.
Hui MM, Merani R, Bonar F, Hong AM, Fung AT. Hui MM, et al. Among authors: hong am. Am J Ophthalmol Case Rep. 2019 Feb 22;14:55-57. doi: 10.1016/j.ajoc.2019.02.009. eCollection 2019 Jun. Am J Ophthalmol Case Rep. 2019. PMID: 30886937 Free PMC article.
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.
McCaughan GJ, Fulham MJ, Mahar A, Soper J, Hong AM, Stalley PD, Tattersall MH, Bhadri VA. McCaughan GJ, et al. Among authors: hong am. J Hematol Oncol. 2016 Jun 3;9(1):48. doi: 10.1186/s13045-016-0278-x. J Hematol Oncol. 2016. PMID: 27259563 Free PMC article.
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z. Bonvalot S, et al. Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8. Lancet Oncol. 2019. PMID: 31296491 Clinical Trial.
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma.
Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong AM, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco BJ, Herráez AC, Gronchi A, Sy-Ortin T, Hohenberger P, de Baère T, Cesne AL, Helfre S, Saada-Bouzid E, Anghel RM, Kantor G, Montero A, Loong HH, Vergés R, Kacso G, Austen L, Servois VF, Wardelmann E, Dimitriu M, Said P, Lazar AJ, Bovée JVMG, Péchoux CL, Pápai Z. Bonvalot S, et al. Among authors: hong am. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):422-432. doi: 10.1016/j.ijrobp.2022.07.001. Epub 2022 Jul 16. Int J Radiat Oncol Biol Phys. 2022. PMID: 35850363 Free article. Clinical Trial.
Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, Long GV, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF. Hong AM, et al. J Clin Oncol. 2019 Nov 20;37(33):3132-3141. doi: 10.1200/JCO.19.01414. Epub 2019 Sep 25. J Clin Oncol. 2019. PMID: 31553661 Clinical Trial.
83 results